Skip to content

Study · Randomized controlled trial · n = 10 · 1998

2 results

Nebulized glucagon in the treatment of bronchospasm in asthmatic patients.

Melanson SW, Bonfante G, Heller MB

The American journal of emergency medicine1 May 1998Cited by 9 (Europe PMC)

PMID9596431 (opens in a new tab)DOI10.1016/s0735-6757(98)90100-0 (opens in a new tab)PepBankPUB-09596431
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In asthmatic subjects, glucagon improved FEV1 by 58% +/- 15% versus 36% +/- 7% with saline at 15 minutes (P < .05).

    In plain wordsIn asthmatic subjects, nebulized glucagon improved breathing volume more than saline at 15 minutes.

    Peptide
    Glucagon
    Outcome
    IncreaseFEV1 improvement at 15 minutes
    Study

    n = 10

    Comparator
    Nebulized saline
    Outcome group
    Respiratory function · Respiratory
    Studied dose
    2 mg · nebulizedAs given in this study (human).

    Measurements

    FEV1 improvement
    58%
    nebulized glucagon, 15 minutes after treatment; +/- 15
    FEV1 improvement
    36%
    nebulized saline, 15 minutes after treatment; +/- 7

    Source sentences

    Summary
    Treatment with nebulized glucagon resulted in a 58% +/- 15% improvement in FEV1 15 minutes after treatment compared with 36% +/- 7% after nebulized saline (P < .05).
    3 context sentences
    Summary · context
    Ten subjects, aged 12 to 26 years, with chronic stable asthma were studied in a pulmonary function laboratory under a randomized double-blind, placebo-controlled, crossover design.
    Summary · context
    Bronchospasm was induced in each subject with progressive doses of nebulized methacholine until forced expiratory volume in 1 second (FEV1) had decreased at least 20% from baseline.
    Summary · context
    Subjects then received either nebulized saline or 2 mg of nebulized glucagon.
  2. 02HumanNon-randomized trialSafety outcome

    In asthmatic subjects, nebulized glucagon produced no adverse effects.

    In plain wordsIn asthmatic subjects, no adverse effects occurred after nebulized glucagon.

    Peptide
    Glucagon
    Outcome
    Not applicableAdverse effects
    Study

    n = 10

    Outcome group
    Adverse events · Whole body
    Studied dose
    2 mg · nebulizedAs given in this study (human).

    Source sentences

    Summary
    No adverse effects of glucagon treatment occurred.
    3 context sentences
    Summary · context
    Ten subjects, aged 12 to 26 years, with chronic stable asthma were studied in a pulmonary function laboratory under a randomized double-blind, placebo-controlled, crossover design.
    Summary · context
    Bronchospasm was induced in each subject with progressive doses of nebulized methacholine until forced expiratory volume in 1 second (FEV1) had decreased at least 20% from baseline.
    Summary · context
    Subjects then received either nebulized saline or 2 mg of nebulized glucagon.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.